Press Releases
Etubics Platform Generates Solid Immune Response in Colorectal Cancer Patients
Additional Deletions in Ad5 Platform Allow For Multiple Immunizations Despite Ad5 Immunity SEATTLE (May 6, 2013) - Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary vaccine platform that results in a long lasting "active" immune...
Gilbert S. Omenn Joins Etubics Board of Directors
SEATTLE – Etubics Corporation announces the election of Gilbert S. Omenn, MD, PhD, to its Board of Directors. “Dr. Omenn is a welcome addition to Etubics' Board,” said Dr. Frank Jones, chief executive officer, chairman of the board and founder of Etubics. "His vast...
Etubics Platform Controls HIV and H1N1 Infection in Animal Model
SEATTLE (December 18, 2012) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform vaccine technology that delivers a long lasting "active" immune response against diseases, announced that Vaccine has published a peer reviewed...
HPV Vaccine Enhances Treatment of HPV Expressing Cancer in Animals
SEATTLE (September 19, 2012) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform vaccine technology that delivers a long lasting "active" immune response against diseases, and Sanford Research in South Dakota announced that...
Etubics and Duke Cancer Institute Report Positive Phase I/II Results for Colorectal Cancer Immunotherapy
SEATTLE (May 16, 2012) - Etubics Corporation, a bio-pharmaceutical company with a platform technology that delivers a long lasting "active" immune response against diseases, and Duke Cancer Institute will present a review of a collaborative first-in-man Phase I/II...
Etubics AD5 Platform Overcomes AD5 Immunity in Multiple Studies
Clinical & Cellular Immunology Review Shows Company Can Break Ad5 Immunity Tolerance SEATTLE (December 21, 2011) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform technology that can be used to rapidly develop both...
Etubics HIV Vaccine Overcomes AD5 Immunity in AD5 Immunized Non-Human Primates
SEATTLE (October 13, 2011) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform technology that can be used to rapidly develop immunotherapeutics and preventive vaccines, announced today that novel data from a preclinical...
Etubics Awarded $1,698,989 in Manufacturing Contracts from National Cancer Institute
SEATTLE (September 22, 2011) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform technology that can be used to rapidly develop immunotherapeutics and preventive vaccines, announced today that it was awarded two contracts...
Etubics H1N1 Vaccine Inhibits Horizontal Transmission in Ferrets
Etubics Platform Enables the Rapid Production of H1N1 Vaccine, Making It Ideal for Pandemics SEATTLE (August 16, 2011) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform technology that can be used to rapidly develop...
Etubics Awarded Grant for HPV Induced Cancers
SEATTLE (July 5, 2011) – Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary platform technology that can be used to rapidly develop immunotherapeutics and preventive vaccines for a wide range of diseases, announced today that it was...